
- /
- Supported exchanges
- / US
- / LIPO.NASDAQ
Lipella Pharmaceuticals Inc. Common Stock (LIPO NASDAQ) stock market data APIs
Lipella Pharmaceuticals Inc. Common Stock Financial Data Overview
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Lipella Pharmaceuticals Inc. Common Stock data using free add-ons & libraries
Get Lipella Pharmaceuticals Inc. Common Stock Fundamental Data
Lipella Pharmaceuticals Inc. Common Stock Fundamental data includes:
- Net Revenue: 520 K
- EBITDA: -5 187 830
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Lipella Pharmaceuticals Inc. Common Stock Earnings data
What’s included:
- Latest Release: 2025-05-28
- EPS/Forecast: NaN
Get Lipella Pharmaceuticals Inc. Common Stock End-of-day data
EOD Historical Data package for
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Lipella Pharmaceuticals Inc. Common Stock News

Lipella stock tumbles after Nasdaq delisting over rule violations
Investing.com -- Lipella Pharmaceuticals Inc (OTC:LIPO) stock plunged 23% after the clinical-stage biotechnology company was delisted from the Nasdaq Capital Market due to rule violations related to...


Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology
* Lipella Pharmaceuticals (NASDAQ:LIPO [https://seekingalpha.com/symbol/LIPO]) on Tuesday announced the issuance of U.S. Patent No. 12,326,492, titled _“Systems and Methods of Detecting Interstiti...

Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology
PITTSBURGH, June 17, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies...

Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development
PITTSBURGH, June 04, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.